Lindsay D A, Russell N L, Thompson J E, Warnock T H, Shellshear I D, Buchanan P R
Astra Pharmaceuticals Pty. Ltd, North Ryde, NSW, Australia.
Eur Respir J. 1994 Feb;7(2):342-5. doi: 10.1183/09031936.94.07020342.
Twenty seven adults and 20 children with previously diagnosed stable asthma, using a salbutamol pressurized metered dose inhaler (P-MDI) and living in Cairns, Townsville and Southport, Queensland, Australia participated in a randomized, open-label cross-over comparison of terbutaline administered via Turbuhaler and salbutamol administered via P-MDI. The aim of the study was to compare the clinical effectiveness and patient acceptance of the two treatments in hot, humid regions. Terbutaline was administered via Turbuhaler and salbutamol via P-MDI on at least two occasions per day during each four week treatment period. Spirometry was performed at the start of the study, after the two week run-in and at the end of each treatment period. Patients used diary cards to record morning and evening peak expiratory flows, daily symptom scores and daily intake of beta 2 agonist medication. At the end of the study, patients answered a treatment preference question. Forty six patients completed the study. No statistically significant differences were observed between the two treatments in peak expiratory flow, change in morning peak expiratory flow pre- and post-beta-agonist, daily symptom scores, diurnal variability and spirometry. Forty four percent of patients preferred the terbutaline Turbuhaler and 39% preferred salbutamol P-MDI. Both agents were similarly tolerated. Terbutaline delivered by Turbuhaler is as clinically effective as salbutamol delivered by P-MDI in patients with asthma living in hot, humid regions.
27名成年人和20名先前已确诊为稳定型哮喘的儿童参与了一项随机、开放标签的交叉对照试验，这些患者使用沙丁胺醇压力定量气雾剂（P-MDI），居住在澳大利亚昆士兰州的凯恩斯、汤斯维尔和南港。该研究旨在比较在炎热潮湿地区使用都保装置吸入特布他林与使用P-MDI吸入沙丁胺醇这两种治疗方法的临床疗效和患者接受度。在每个为期四周的治疗期内，每天至少两次通过都保装置吸入特布他林，通过P-MDI吸入沙丁胺醇。在研究开始时、两周导入期后以及每个治疗期结束时进行肺功能测定。患者使用日记卡记录早晚的呼气峰值流速、每日症状评分以及β2激动剂药物的每日摄入量。在研究结束时，患者回答一个关于治疗偏好的问题。46名患者完成了研究。在呼气峰值流速、β激动剂使用前后的早晨呼气峰值流速变化、每日症状评分、昼夜变异性和肺功能测定方面，两种治疗方法之间未观察到统计学上的显著差异。44%的患者更喜欢特布他林都保装置，39%的患者更喜欢沙丁胺醇P-MDI。两种药物的耐受性相似。对于居住在炎热潮湿地区的哮喘患者，通过都保装置吸入的特布他林在临床上与通过P-MDI吸入的沙丁胺醇效果相当。
